Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 4/20 | 0.67 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.56 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 4/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5013585 | 1.00 | NNMT (0.67) | NNMTPARP10MKNK1MKNK2SMN1; SMN2 | |
| SCHEMBL29146673 | 0.90 | NNMT (0.55) | NNMTPARP10MKNK1MKNK2SMN1; SMN2 | |
| SCHEMBL14480387 | 0.84 | ACACB (0.48) | NNMTPARP10ALDH1A1ACACBACACA | |
| SCHEMBL841924 | 0.84 | MAPT (0.62) | NNMTALDH1A1ACACBMAPTL3MBTL1 | |
| SCHEMBL21669621 | 0.83 | NNMT (0.62) | NNMTPARP10MKNK1MKNK2SMN1; SMN2 | |
| SCHEMBL17984748 | 0.83 | FURIN (0.46) | NNMTPARP10ALDH1A1ACACBACACA | |
| SCHEMBL27875916 | 0.83 | ALDH1A1 (0.46) | NNMTPARP10ALDH1A1ACACBACACA | |
| SCHEMBL3590924 | 0.81 | CA12 (0.51) | NNMTSMN1; SMN2ALDH1A1ACACBMAPT | |
| SCHEMBL29975550 | 0.80 | NNMT (1.00) | NNMTPARP10MKNK1MKNK2SMN1; SMN2 | |
| SCHEMBL71905 | 0.80 | NNMT (1.00) | NNMTPARP10MKNK1MKNK2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118251389-A | Pyridyl derivatives as sodium channel activators | 泽农医药公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NNMT 1377/4885PARP10 1592/4885MKNK1 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.